Skip to main content
    L

    LENSAR Inc (LNSR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.29
    +0.29 (+5.80%)

    Market Cap: $61.47M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    LENSAR Inc (LNSR) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    LENSAR (LNSR) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, LENSAR reported EPS of -$0.11, above the -$0.14 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    56%(14/25)
    Avg Surprise
    -32.24%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.09
    Range-$0.10 - -$0.07
    5 analysts
    Revenue Consensus
    $17.20M
    Range$15.68M - $18.48M
    5 analysts
    Reports May 6, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.17
    Range-$0.17 - -$0.17
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$0.17
    Revenue Consensus
    $15.80M
    Range$14.80M - $17.60M
    3 analysts

    Next Report

    LNSR has an expected report date of Feb 25, 2027.

    LNSR Earnings Call

    The latest LNSR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 25 quarters below that had an estimate, LNSR beat 14 and missed 11. Revenue for the quarter ended Sep 30, 2026 was $14.13M, down 1.3% from $14.32M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.11-$0.14-$0.14 - -$0.14+21.79%BeatN/A10 up, 0 downNov 10, 2026$14.13M
    Jun 30, 2026$0.10-$0.27-$0.27 - -$0.27+137.04%BeatN/A10 up, 0 downAug 13, 2026$16.50M
    Mar 31, 2026-$0.20$0.49$0.49 - $0.49-140.08%MissN/A10 up, 0 downMay 8, 2026$13.43M
    Dec 31, 2025-$0.12-$0.07N/A-71.43%MissN/A10 up, 1 downMar 31, 2026$16.02M
    Sep 30, 2025-$0.11-$0.08-$0.11 - -$0.05-37.50%MissN/A20 up, 1 downNov 6, 2025$14.32M
    Jun 30, 2025-$0.15-$0.07-$0.13 - -$0.02-114.29%MissN/A20 up, 1 downAug 7, 2025$13.94M
    Mar 31, 2025-$0.06-$0.15-$0.17 - -$0.14+60.00%BeatN/A20 up, 1 downMay 8, 2025$14.16M
    Dec 31, 2024-$0.10-$0.18-$0.22 - -$0.14+45.50%BeatN/A20 up, 1 downFeb 27, 2025$16.73M
    Sep 30, 2024-$0.09-$0.29-$0.33 - -$0.26+68.97%BeatN/A20 up, 0 downNov 7, 2024$13.54M
    Jun 30, 2024-$0.12-$0.29-$0.30 - -$0.29+58.62%BeatN/A20 up, 0 downAug 8, 2024$12.64M
    Mar 31, 2024-$0.19-$0.28-$0.38 - -$0.19+32.14%BeatN/A20 up, 0 downMay 9, 2024$10.59M
    Dec 31, 2023-$0.35-$0.22-$0.22 - -$0.22-59.09%MissN/A10 up, 0 downMar 4, 2024$12.11M
    Sep 30, 2023-$0.28-$0.34-$0.34 - -$0.34+17.65%BeatN/A10 up, 0 downNov 9, 2023$9.79M
    Jun 30, 2023-$0.25-$0.35-$0.35 - -$0.35+28.57%BeatN/A11 up, 0 downAug 9, 2023$12.01M
    Mar 31, 2023-$0.40-$0.27-$0.27 - -$0.27-48.15%MissN/A10 up, 0 downMay 15, 2023$8.25M
    Dec 31, 2022-$0.24-$0.25-$0.25 - -$0.25+4.00%BeatN/A10 up, 0 downMar 16, 2023$10.23M
    Sep 30, 2022-$0.39-$0.62-$0.62 - -$0.62+37.10%BeatN/A10 up, 0 downNov 9, 2022$7.75M
    Jun 30, 2022-$0.67-$0.72-$0.72 - -$0.72+6.94%BeatN/A10 up, 0 downAug 8, 2022$8.04M
    Mar 31, 2022-$0.67-$0.58-$0.88 - -$0.58-15.52%MissN/A20 up, 0 downMay 9, 2022$9.34M
    Dec 31, 2021-$0.41-$0.52-$0.60 - -$0.44+21.15%BeatN/A20 up, 0 downMar 3, 2022$11.22M
    Sep 30, 2021-$0.65-$0.59-$0.59 - -$0.59-10.17%MissN/A1N/ANov 8, 2021$8.27M
    Jun 30, 2021-$0.47-$0.59N/A+20.34%BeatN/A1N/AAug 5, 2021$7.92M
    Mar 31, 2021-$0.56-$0.33-$0.33 - -$0.33-69.70%MissN/A1N/AMay 5, 2021$7.04M
    Dec 31, 2020-$0.78-$0.52N/A-50.00%MissN/AN/AN/AMar 10, 2021$12.86M
    Sep 30, 2020-$5.44-$0.64N/A-750.00%MissN/AN/AN/ANov 9, 2020$7.14M
    Jun 30, 2020-$13.70N/AN/AN/AN/AN/AN/AN/AAug 26, 2020$470000
    Mar 31, 2020-$0.42N/AN/AN/AN/AN/AN/AN/AJun 30, 2020$5.91M
    Dec 31, 2019-$0.42N/AN/AN/AN/AN/AN/AN/AMar 30, 2020$8.46M
    Jun 30, 2019-$5.44N/AN/AN/AN/AN/AN/AN/ASep 30, 2019$7.00M
    Mar 31, 2019-$0.33N/AN/AN/AN/AN/AN/AN/AJun 29, 2019$7.00M
    Dec 31, 2018-$0.33N/AN/AN/AN/AN/AN/AN/AMar 30, 2019N/A
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.44, after -$0.50 the year before. It was -$0.33 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.44N/A
    Dec 31, 2024-$0.50N/A
    Dec 31, 2023-$1.28N/A
    Dec 31, 2022-$1.97N/A
    Dec 31, 2021-$2.09N/A
    Dec 31, 2020-$20.34N/A
    Dec 31, 2019-$6.19N/A
    Dec 31, 2018-$0.33N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,3067
    2026Q2Jun 30, 20263,7756
    2026Q1Mar 31, 20264,8606
    2025Q4Dec 31, 20255,3236
    2024Q4Dec 31, 20244,1016
    2024Q3Sep 30, 20244,2525

    2026Q3 Earnings Call

    Opening remarks

    Lee Roth Investor Relations Adviser Thanks, Audra. Good morning, everyone, and welcome to the LENSAR Third Quarter Financial Results Conference Call. Earlier this morning, we issued a press release providing an overview of our financial results for the third quarter of 2026 ended September 30. This release is available on the Investor Relations section of our website at www.lensar.com. Joining me on the call today is Nick Curtis, Chief Executive Officer, and Mike Rossi, Interim Chief Financial Officer of LENSAR, who will provide an overview of recent developments, operational highlights and financial results. Following these prepared remarks, we'll turn the call back over to the operator to take your questions. Before we begin, I'd like to remind you all that today's call will contain forward-looking statements, including statements regarding our future results, unaudited and forward-looking financial information, as well as information on our future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or otherwise implied during this call. You should not place any undue reliance on these forward-looking statements. For additional information, including a detailed discussion of the company's risk factors, please refer to our documents filed with the Securities and Exchange Commission, which can be accessed on the website. In addition, this call contains time-sensitive information accurate only as of the date of this live broadcast, Tuesday, November 10, 2026. LENSAR undertakes no obligation to revise or otherwise update any forward-looking statements to reflect events or circumstances that occur after the date of this live call. With that said, it's now my pleasure to turn the call over to our CEO, Nick Curtis. Nick?

    Nicholas Curtis CEO Thank you, Lee. Before getting into the quarter, I'd really like to put our results into context. As we discussed on our second quarter call in August, the third quarter is historically the slowest period of the year in our space, reflecting summer vacations and extended holidays in various regions of the world and the timing of surgical schedules, including purchasing decisions. In addition, timing-wise, we were just getting back on track after the disruption earlier this year. No surprise that seasonality was evident in our results, particularly compared to what was an extremely solid second quarter against a year-ago period that saw a bolus of ALLY system sales and placements. To be clear, this performance was consistent with what we had anticipated. More importantly, the underlying indicators we focus on to assess the foundational health of the business, including procedure volume, recurring revenue and the growth of our installed base, continue to move in the positive direction on a year-over-year basis.

    Frequently Asked Questions About LNSR

    When is LENSAR's next earnings date?

    LENSAR's next earnings report is expected for Feb 25, 2027.

    Did LNSR beat earnings estimates last quarter?

    Yes. LENSAR reported EPS of -$0.11 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 21.79% surprise.

    What EPS do analysts expect from LNSR next quarter?

    The consensus EPS estimate for LENSAR for the quarter ending Dec 31, 2026 is -$0.09 from 5 analysts, with estimates from -$0.10 to -$0.07.

    How often does LNSR beat earnings estimates?

    LENSAR beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -12.37%.